retatrutide phase 2 trial type 2 diabetes results 2024 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Triple hormone receptor agonist retatrutide

Abstract Dopamine directly acts in the liver and white adipose tissue (WAT) to regulate insulin signaling, glucose uptake, and catabolic activity

2021 Mar 30;30(1):32-43

Retatrutide is not an approved therapy, and any compound offered under this name is intended solely for laboratory investigation, not for human consumption

Montero A et al, KFF Health Tracking Poll May 2024: The Publics Use and Views of GLP-1 Drugs

As with many prescription medications, women who are pregnant or planning to become pregnant should not take Saxenda

Strategies like protein pacing can be valuable for streamlining nutrition, ensuring you hit your quotas